MicroRNA-433 targets AKT3 and inhibits cell proliferation and viability in breast cancer

Hu,Xiaolei; Wang,Jie; He,Wan; Zhao,Pan; Ye,Changsheng

doi:10.3892/ol.2018.7803

MicroRNA-433 targets AKT3 and inhibits cell proliferation and viability in breast cancer

Authors:
- Xiaolei Hu
- Jie Wang
- Wan He
- Pan Zhao
- Changsheng Ye
View Affiliations

Affiliations: Department of Breast Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Clinical Nutrition Department, The 458th Hospital of People's Liberation Army, Guangzhou, Guangdong 510620, P.R. China, Department of Oncology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen, Guangdong 518000, P.R. China, Department of Clinical Medical Research, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen, Guangdong 518000, P.R. China
Published online on: January 16, 2018 https://doi.org/10.3892/ol.2018.7803
Pages: 3998-4004

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most frequently diagnosed malignancy in women. However, the molecular mechanisms underlying breast cancer pathogenesis are not fully understood. The present study examined the role of miR‑433 in breast cancer and investigated its underlying molecular mechanisms of action. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis were performed to analyze the level of microRNA (miRNA/miR)/mRNA and protein expression, respectively. Additionally, MTT assay was used to determined cell proliferation and viability. Cell apoptosis was measured by flow cytometry. A dual‑luciferase reporter assay was used to confirm the identity of the downstream target of miR‑433. The results revealed that miR‑433 was downregulated in breast cancer tissues and cell lines. Overexpression of miR‑433 inhibited cell proliferation and cell viability in BT‑549 cells, whereas downregulation of miR‑433 increased cell proliferation and cell viability in MDA‑MB‑231 cells. Further flow cytometry analysis revealed that miR‑433 was able to induce apoptosis and also alter the levels of proteins expression of B‑cell lymphoma‑2 and Bcl‑associated X. Bioinformatics analysis showed that RAC‑γ serine/threonine‑protein kinase (AKT3) was one of the downstream targets of miR‑433, and luciferase reporter assay further confirmed that AKT3 is a direct target of miR‑433. The knockdown of AKT3 was able to inhibit proliferation and viability in BT‑549 cells. Overexpression of AKT3 prevented the inhibitory effects of miR‑433 on proliferation and viability in BT‑549 cells. The level of AKT3 mRNA expression was upregulated in breast cancer tissues compared with normal tissues and was inversely correlated with miR‑433 expression levels. In summary, the results of the present study results indicate that the tumor‑suppressive role of miR‑433 may be mediated by regulating AKT3. miR‑433 may therefore serve as a potential therapeutic target for breast cancer.

View Figures

View References

1	Rudolph A, Chang-Claude J and Schmidt MK: Gene-environment interaction and risk of breast cancer. Br J Cancer. 114:125–133. 2016. View Article : Google Scholar : PubMed/NCBI
2	Li C, Yang L, Zhang D and Jiang W: Systematic review and meta-analysis suggest that dietary cholesterol intake increases risk of breast cancer. Nutr Res. 36:627–635. 2016. View Article : Google Scholar : PubMed/NCBI
3	Srivastava S, Reid BJ, Ghosh S and Kramer BS: Research needs for understanding the biology of overdiagnosis in cancer screening. J Cell Physiol. 231:1870–1875. 2016. View Article : Google Scholar : PubMed/NCBI
4	Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V and Grech G: Breast cancer epidemic in the early twenty-first century: Evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumour Biol. 37:12941–12957. 2016. View Article : Google Scholar : PubMed/NCBI
5	Sonnenblick A, Pondé N and Piccart M: Metastatic breast cancer: The Odyssey of personalization. Mol Oncol. 10:1147–1159. 2016. View Article : Google Scholar : PubMed/NCBI
6	Tzanninis IG, Kotteas EA, Ntanasis-Stathopoulos I, Kontogianni P and Fotopoulos G: Management and outcomes in metaplastic breast cancer. Clin Breast Cancer. 16:437–443. 2016. View Article : Google Scholar : PubMed/NCBI
7	Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh F, Asghari F and Yousefi M: The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed Pharmacother. 78:129–139. 2016. View Article : Google Scholar : PubMed/NCBI
8	Pinweha P, Rattanapornsompong K, Charoensawan V and Jitrapakdee S: MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers. Comput Struct Biotechnol J. 14:223–233. 2016. View Article : Google Scholar : PubMed/NCBI
9	Leung AK: The Whereabouts of microRNA Actions: Cytoplasm and beyond. Trends Cell Biol. 25:601–610. 2015. View Article : Google Scholar : PubMed/NCBI
10	Li X, Yang L, Shuai T, Piao T and Wang R: MiR-433 inhibits retinoblastoma malignancy by suppressing Notch1 and PAX6 expression. Biomed Pharmacother. 82:247–255. 2016. View Article : Google Scholar : PubMed/NCBI
11	Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A, Sharpe D, et al: Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med. 4:745–758. 2015. View Article : Google Scholar : PubMed/NCBI
12	Wang XC, Ma Y, Meng PS, Han JL, Yu HY and Bi LJ: miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6. Oral Oncol. 51:674–682. 2015. View Article : Google Scholar : PubMed/NCBI
13	Guo LH, Li H, Wang F, Yu J and He JS: The tumor suppressor roles of miR-433 and miR-127 in gastric cancer. Int J Mol Sci. 14:14171–14184. 2013. View Article : Google Scholar : PubMed/NCBI
14	Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X and Gan J: A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 9:e1079862014. View Article : Google Scholar : PubMed/NCBI
15	Del Vescovo V, Meier T, Inga A, Denti MA and Borlak J: A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice. PLoS One. 8:e788702013. View Article : Google Scholar : PubMed/NCBI
16	Xu X, Zhu Y, Liang Z, Li S, Xu X, Wang X, Wu J, Hu Z, Meng S, Liu B, et al: c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling. Cell Death Dis. 7:e20882016. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
19	Luo H, Zhang H, Zhang Z, Zhang X, Ning B, Guo J, Nie N, Liu B and Wu X: Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer Res. 28:822009. View Article : Google Scholar : PubMed/NCBI
20	Wang K, Li L, Wu J, Qiu Q, Zhou F and Wu H: The different expression profiles of microRNAs in elderly and young human dental pulp and the role of miR-433 in human dental pulp cells. Mech Ageing Dev 146–148. 1–11. 2015. View Article : Google Scholar
21	Dillon RL and Muller WJ: Distinct biological roles for the akt family in mammary tumor progression. Cancer Res. 70:4260–4264. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chin YR and Toker A: Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal. 21:470–476. 2009. View Article : Google Scholar : PubMed/NCBI
23	Sultana A, Idress R, Naqvi ZA, Azam I, Khan S, Siddiqui AA and Lalani EN: Expression of the androgen receptor, pAkt, and pPTEN in breast cancer and their potential in prognostication. Transl Oncol. May 12–2014.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
24	Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K and Toker A: Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res. 74:964–973. 2014. View Article : Google Scholar : PubMed/NCBI
25	Grottke A, Ewald F, Lange T, Nörz D, Herzberger C, Bach J, Grabinski N, Gräser L, Höppner F, Nashan B, et al: Downregulation of AKT3 increases migration and metastasis in triple negative breast cancer cells by upregulating S100A4. PLoS One. 11:e01463702016. View Article : Google Scholar : PubMed/NCBI
26	Mosquera JM, Varma S, Pauli C, MacDonald TY, Yashinskie JJ, Varga Z, Sboner A, Moch H, Rubin MA and Shin SJ: MAGI3-AKT3 fusion in breast cancer amended. Nature. 520:E11–E12. 2015. View Article : Google Scholar : PubMed/NCBI
27	O'Hurley G, Daly E, O'Grady A, Cummins R, Quinn C, Flanagan L, Pierce A, Fan Y, Lynn MA, Rafferty M, et al: Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. Histopathology. 64:660–670. 2014. View Article : Google Scholar : PubMed/NCBI
28	Stottrup C, Tsang T and Chin YR: Upregulation of AKT3 confers resistance to the AKT inhibitor MK2206 in breast cancer. Mol Cancer Ther. 15:1964–1974. 2016. View Article : Google Scholar : PubMed/NCBI
29	Waugh MG: Amplification of chromosome 1q genes encoding the phosphoinositide signalling enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in breast cancer. J Cancer. 5:790–796. 2014. View Article : Google Scholar : PubMed/NCBI